Epidemiology, risk factors and mechanism of breast cancer and atrial fibrillation.

IF 3.2 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Cardio-oncology Pub Date : 2024-12-23 DOI:10.1186/s40959-024-00298-y
Xiaoxue Guo, Zheng Zuo, Xishu Wang, Ying Sun, Dongyang Xu, Guanghui Liu, Yi Tong, Zhiguo Zhang
{"title":"Epidemiology, risk factors and mechanism of breast cancer and atrial fibrillation.","authors":"Xiaoxue Guo, Zheng Zuo, Xishu Wang, Ying Sun, Dongyang Xu, Guanghui Liu, Yi Tong, Zhiguo Zhang","doi":"10.1186/s40959-024-00298-y","DOIUrl":null,"url":null,"abstract":"<p><p>Cancer and cardiovascular diseases are leading causes of death worldwide. Among them, breast cancer is one of the most common malignancies in women, while atrial fibrillation is one of the most extensively studied arrhythmias, with significant public health implications. As the global population ages and advancements in cancer treatments continue, the survival rates of breast cancer patients have significantly improved, leading to an increasing coexistence of breast cancer and atrial fibrillation. However, the mechanisms underlying this coexistence remain insufficiently studied, and there is no consensus on the optimal treatment strategies for these patients. This review consolidates existing research to systematically explore the epidemiological characteristics, risk factors, and pathophysiological mechanisms of both breast cancer and atrial fibrillation. It focuses on the unique signaling pathways associated with different molecular subtypes of breast cancer and their potential impact on the mechanisms of atrial fibrillation. Additionally, the relationship between atrial fibrillation treatment medications and breast cancer is discussed. These insights not only provide essential evidence for the precise prevention and management of atrial fibrillation in breast cancer patients but also lay a solid theoretical foundation for interdisciplinary clinical management practices.</p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":"10 1","pages":"92"},"PeriodicalIF":3.2000,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11665102/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardio-oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40959-024-00298-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Cancer and cardiovascular diseases are leading causes of death worldwide. Among them, breast cancer is one of the most common malignancies in women, while atrial fibrillation is one of the most extensively studied arrhythmias, with significant public health implications. As the global population ages and advancements in cancer treatments continue, the survival rates of breast cancer patients have significantly improved, leading to an increasing coexistence of breast cancer and atrial fibrillation. However, the mechanisms underlying this coexistence remain insufficiently studied, and there is no consensus on the optimal treatment strategies for these patients. This review consolidates existing research to systematically explore the epidemiological characteristics, risk factors, and pathophysiological mechanisms of both breast cancer and atrial fibrillation. It focuses on the unique signaling pathways associated with different molecular subtypes of breast cancer and their potential impact on the mechanisms of atrial fibrillation. Additionally, the relationship between atrial fibrillation treatment medications and breast cancer is discussed. These insights not only provide essential evidence for the precise prevention and management of atrial fibrillation in breast cancer patients but also lay a solid theoretical foundation for interdisciplinary clinical management practices.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
乳腺癌与房颤的流行病学、危险因素及发病机制。
癌症和心血管疾病是全世界的主要死亡原因。其中,乳腺癌是女性最常见的恶性肿瘤之一,而房颤是研究最广泛的心律失常之一,具有重要的公共卫生意义。随着全球人口老龄化和癌症治疗的不断进步,乳腺癌患者的生存率显著提高,导致乳腺癌和房颤共存的情况越来越多。然而,这种共存的机制仍然没有得到充分的研究,对于这些患者的最佳治疗策略也没有达成共识。本综述整合现有研究,系统探讨乳腺癌和房颤的流行病学特征、危险因素和病理生理机制。它侧重于与乳腺癌不同分子亚型相关的独特信号通路及其对房颤机制的潜在影响。此外,还讨论了房颤治疗药物与乳腺癌的关系。这些见解不仅为乳腺癌患者房颤的精准预防和管理提供了必要的证据,也为跨学科临床管理实践奠定了坚实的理论基础。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cardio-oncology
Cardio-oncology Medicine-Cardiology and Cardiovascular Medicine
CiteScore
5.00
自引率
3.00%
发文量
17
审稿时长
7 weeks
期刊最新文献
Incidence and survival outcomes of myocarditis and pericardial diseases associated with immune checkpoint inhibitor therapy. Is the pendulum slowly starting to swing back? Exercise and cardiovascular health among breast cancer survivors: a scoping review of current observational evidence. Incidence and risk factors of trastuzumab-induced cardiac dysfunction in a predominantly Hispanic South Texas population: a descriptive study. Survivorship clinic attendance improves completion but not timeliness of cardiac surveillance post anthracyclines.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1